Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CDMO

Navin Fluorine shares surge 8% after Q1 profit more than doubles. Should you buy, sell or hold?

Navin Fluorine shares surged nearly 8% after the company posted a strong Q1FY27 performance, with profit more than doubling and revenue rising 44% YoY. Elara Securities retained its 'Buy' rating and Rs 9,158 target, citing robust growth in refrigerants, specialty chemicals and CDMO, along with a strong expansion pipeline that…

The Economic Times

India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life Sciences

India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life Sciences

Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like Sai Life Sciences are investing heavily in capacity, anticipating a surge in demand. While regulatory processes mean benefits will be gradual, this supply-chain realignment presents a landmark opportunity for India's CDMO sector,…

The Economic Times

Dark Horse Consulting Group and Altruist Biologics Announce Memorandum of Understanding to Advance Biologics Manufacturing and Development in China

WALNUT CREEK, Calif. and SUZHOU, China, June 03, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Altruist Biologics, a wholly-owned subsidiary of Innovent Biologics and global contract development and manufacturing organization (CDMO) specializing in the development and…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

AI-linked hiring in CDMO industry jumps nearly 3-fold in 2 years: Report

Artificial intelligence skill demand in India's Contract Development and Manufacturing Organisation sector is set to surge. Demand for AI skills in CDMOs will nearly triple between 2023 and 2025. This reflects a significant shift towards automation and advanced capabilities. Manufacturing and operations remain key areas. However, a talent gap is…

The Economic Times

AGC Biologics to Manufacture Teikoku Seiyaku's rhMMP-7 Drug Substance

HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc…

Deepa Jewellers, Cotec Healthcare receive Sebi approval for IPOs

Deepa Jewellers, a B2B hallmarked gold jewellery processor based in Hyderabad, and Cotec Healthcare, a pharmaceutical CDMO, both received SEBI approval for their IPOs. Deepa's IPO includes a Rs 250 crore fresh issue and an offer for sale by promoters.

The Economic Times

Buy the chaos: Why Kashyap Javeri says market volatility is an investor's best friend right now

Fund Manager Kashyap Javeri views market corrections as opportunities, not warnings. He advocates for investing during volatility, highlighting recent payoffs for those who entered fresh positions or topped up existing ones during the March dip. Javeri is strategically investing in auto ancillaries, capital goods, private banks, and pharma (CDMO), while…

The Economic Times

inkl

Read news from The Economist, FT, and more,
with one subscription

BioHarvest Sciences Q1 Earnings Call Highlights

BioHarvest Sciences (NASDAQ:BHST) reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, plat

Is Your Portfolio Healthy? Don't Touch This Stock With a Ten-Foot Pole!

Is Your Portfolio Healthy? Don't Touch This Stock With a Ten-Foot Pole!

Amidst lingering economic uncertainties, pharma contract development company Avid Bioservices (CDMO) has been flashing red flags with deteriorating financial results in the last reported quarter and bleak prospects. Therefore, I think this fundamentally weak stock might be best avoided. Keep reading.

Read How Avid Bioservices Fared In Q4

Read How Avid Bioservices Fared In Q4

Avid Bioservices Inc (NASDAQ:CDMO) reported Q4 FY22 sales of $31.2 million, up 13% Y/Y, beating the consensus of $28.96 million. The growth is attributed to an increase in the scope of in-process and completed manufacturing runs and process development revenues. The company signed multiple new project orders during Q4 totaling approximately $44…

Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco

Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco

According to a recent report from the US House select subcommittee on the coronavirus crisis, Emergent Biosolutions Inc (NYSE:EBS) might have destroyed nearly 400 million doses of COVID-19 vaccines after failing to meet quality standards. Initially, 75 million - 85 million doses of drug substance were said to be destroyed after contamination. "Despite major…

Avid Bioservices's Return On Capital Employed Overview

Avid Bioservices's Return On Capital Employed Overview

Pulled from Benzinga Pro data, Avid Bioservices (NASDAQ:CDMO) showed a loss in earnings since Q2, totaling $2.25 million. Sales, on the other hand, increased by 20.68% to $31.51 million during Q3.

Recap: Avid Bioservices Q3 Earnings

Recap: Avid Bioservices Q3 Earnings

Avid Bioservices (NASDAQ:CDMO) reported its Q3 earnings results on Tuesday, March 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Avid Bioservices reported in-line EPS of $0.04 versus an estimate of $0.04.

1

People

206,347 stories

Kritika SarmahHer

Carolyn Maloney

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

AstraZeneca Plc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

404,696 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play